An aggregate Safety Report in the context of clinical trials, considering all newly available safety information reported during a defined period. Where several clinical trials are conducted with the same Investigational Medicinal Product (IMP) the reporter should include a concise global analysis of the actual safety profile of the tested IMP based on the experience for all the clinical trials.